Portola Pharmaceuticals, Inc. (PTLA) Scheduled to Post Quarterly Earnings on Monday
Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) is scheduled to issue its quarterly earnings data after the market closes on Monday, November 6th. Analysts expect the company to announce earnings of ($1.49) per share for the quarter.
Portola Pharmaceuticals (NASDAQ:PTLA) last released its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.22) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.10) by ($0.12). The firm had revenue of $3.79 million during the quarter, compared to analyst estimates of $4.28 million. Portola Pharmaceuticals had a negative net margin of 807.93% and a negative return on equity of 145.12%. Portola Pharmaceuticals’s quarterly revenue was down 10.4% on a year-over-year basis. During the same quarter last year, the firm earned ($1.02) earnings per share. On average, analysts expect Portola Pharmaceuticals to post $-5.04 EPS for the current fiscal year and $-2.85 EPS for the next fiscal year.
Portola Pharmaceuticals, Inc. (NASDAQ PTLA) opened at 49.83 on Monday. The firm’s market capitalization is $2.87 billion. The firm has a 50-day moving average of $53.04 and a 200-day moving average of $50.25. Portola Pharmaceuticals, Inc. has a 52-week low of $15.68 and a 52-week high of $67.10.
A number of equities research analysts have recently weighed in on the stock. Oppenheimer Holdings, Inc. raised their price target on shares of Portola Pharmaceuticals from $66.00 to $80.00 and gave the company an “outperform” rating in a research note on Monday, July 24th. BidaskClub upgraded shares of Portola Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, July 24th. Zacks Investment Research upgraded shares of Portola Pharmaceuticals from a “hold” rating to a “buy” rating and set a $70.00 price target on the stock in a research note on Tuesday, July 18th. Credit Suisse Group set a $70.00 price target on shares of Portola Pharmaceuticals and gave the company a “hold” rating in a research note on Thursday, August 10th. They noted that the move was a valuation call. Finally, Morgan Stanley restated an “overweight” rating and issued a $81.00 price target (up from $75.00) on shares of Portola Pharmaceuticals in a research note on Friday, October 6th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $65.15.
About Portola Pharmaceuticals
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
Receive News & Ratings for Portola Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.